A portion of castration-resistant prostate cancer patients are given abiraterone acetate treatment after docetaxel chemotherapy. In this study, we analyzed the association of patient characteristics and time to castration-resistant prostate cancer (TTCRPC) with secondary hormonal treatment-related progression-free survival. Data of patients whom were treated with Abiraterone Acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC) in two different oncology centers between 2010 and 2018 were analyzed retrospectively. The entire patient group consisted of 76 patients however 13 of them were excluded due to incomplete data. Comparative results were obtained in 63 patients. Mean duration of primary hormonal therapy was 20 months. Docetaxel chemotherapy was administered as 7 cycles and mean duration of remission was 9 months. Mean progression-free survival post-AA treatment was calculated as 27 months. In univariate analysis, prostate specific antigen (PSA) level lower than median PSA at the time of initial diagnosis and a total Gleason score of below 8 was significantly consistent with prolonged progression-free survival (PFS). In multivariete analysis, it was observed that only PSA level at the time of initial diagnosis affected the PFS. Progression-free survival after Abiraterone Acetate treatment in patients with previous hormonal therapy duration longer than 18 months was better than the survival in the patient group who had a shorter hormonal therapy duration. The former group experienced a 39% risk reduction. In the light of these findings, we may recommend the administration of the Androgen Receptor (AR)-targeted treatment option in patients with low PSA levels at the time of diagnosis and patients with long castration duration after chemotherapy.